|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | | | | | | | | | |
|  | **Baseline** | | **8 Weeks** | | **Change** | | **ANCOVA** | | |
|  | **n** | **Mean (SD)** | **n** | **Mean (SD)** | **n** | **Mean (SD)** | **Estimate\*** | **95%CI** | **p** |
| **GLVEF (%)** |  |  |  |  |  |  |  |  |  |
| Placebo | 14 | 39.4 (7.5) | 14 | 45.9 (5.8) | 14 | 6.5 (6.3) | NA |  | NA |
| LD-IGF1 1.5 ng | 13 | 41.2 (9.5) | 15 | 48.5 (13.1) | 13 | 8.2 (7.5) | 1.759 | (-3.355 to 6.873) | 0.505 |
| LD-IGF1 15 ng | 15 | 44.9 (8) | 14 | 50.2 (9.6) | 14 | 4.7 (6.2) | -0.899 | (-6.089 to 4.292) | 0.736 |
| **LVEDV Index (ml/m2)** |  |  |  |  |  |  |  |  |  |
| Placebo | 14 | 96 (16.2) | 14 | 114.5 (20.6) | 14 | 18.5 (14.2) | NA |  | NA |
| LD-IGF1 1.5 ng | 13 | 98.6 (17.3) | 15 | 105.1 (22.4) | 13 | 9.1 (18) | -10.251 | (-23.495 to 2.992) | 0.138 |
| LD-IGF1 15 ng | 15 | 93.6 (9.7) | 14 | 95 (24) | 14 | 2.3 (18.9) | -16.383 | (-29.304 to -3.462) | 0.018 |
| **LVESV Index (ml/m2)** |  |  |  |  |  |  |  |  |  |
| Placebo | 14 | 58.7 (15) | 14 | 62.2 (14.6) | 14 | 3.6 (10.3) | NA |  | NA |
| LD-IGF1 1.5 ng | 13 | 58.8 (17.3) | 15 | 55.4 (21.5) | 13 | -2.6 (15.5) | -6.594 | (-16.85 to 3.663) | 0.216 |
| LD-IGF1 15 ng | 15 | 51.8 (10.4) | 14 | 49.5 (19.2) | 14 | -1.2 (13.4) | -5.351 | (-15.611 to 4.908) | 0.313 |
| **LV Mass Index (g/m2)** |  |  |  |  |  |  |  |  |  |
| Placebo | 10 | 85.8 (17) | 12 | 85 (14.8) | 9 | 0.5 (8.6) | NA |  | NA |
| LD-IGF1 1.5 ng | 9 | 93 (17.1) | 12 | 90.8 (7.2) | 8 | -2 (13.4) | -1.083 | (-10.663 to 8.498) | 0.827 |
| LD-IGF1 15 ng | 15 | 92.5 (19.9) | 13 | 75.9 (18.4) | 13 | -17 (13.4) | -15.484 | (-23.969 to -6.998) | 0.001 |
| **Stroke Volume (ml)** |  |  |  |  |  |  |  |  |  |
| Placebo | 14 | 71.4 (20.3) | 14 | 99.9 (26.1) | 14 | 28.4 (17.8) | NA |  | NA |
| LD-IGF1 1.5 ng | 13 | 74.2 (17.4) | 15 | 92 (27) | 13 | 21.6 (17.2) | -7.801 | (-20.123 to 4.521) | 0.223 |
| LD-IGF1 15 ng | 15 | 83.6 (15.7) | 14 | 94.8 (14.9) | 14 | 10.9 (14.1) | -16.024 | (-28.487 to -3.56) | 0.016 |
| **Late CE** |  |  |  |  |  |  |  |  |  |
| Placebo | 10 | 56.2 (29) | 12 | 49.1 (19.3) | 9 | -12.5 (20.4) | NA |  | NA |
| LD-IGF1 1.5 ng | 10 | 59.2 (34.3) | 12 | 47.4 (22.4) | 9 | -12.4 (21.2) | -1.089 | (-14.022 to 11.845) | 0.87 |
| LD-IGF1 15 ng | 15 | 56.8 (48.7) | 13 | 34.5 (29.6) | 13 | -18.2 (26.2) | -10.448 | (-22.254 to 1.359) | 0.095 |
|  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |
| **LV Mass ED Index** |  |  |  |  |  |  |  |  |  |
| Placebo | 14 | 64.4 (11.5) | 14 | 63 (7.9) | 14 | -1.3 (9) | NA |  | NA |
| LD-IGF1 1.5 ng | 13 | 62.8 (13.7) | 15 | 57.8 (11.1) | 13 | -5.4 (9.6) | -5.217 | (-10.611 to 0.176) | 0.066 |
| LD-IGF1 15 ng | 15 | 67.2 (16.8) | 14 | 56.5 (11.1) | 14 | -11.4 (10.5) | -8.332 | (-13.596 to -3.068) | 0.004 |
| **LV Mass ES Index** |  |  |  |  |  |  |  |  |  |
| Placebo | 14 | 69.3 (11.7) | 14 | 63.1 (8.2) | 14 | -6.3 (8.6) | NA |  | NA |
| LD-IGF1 1.5 ng | 13 | 66.9 (14.8) | 15 | 60.3 (12.9) | 13 | -6.8 (10.4) | -1.664 | (-8.011 to 4.683) | 0.61 |
| LD-IGF1 15 ng | 15 | 68.7 (15) | 14 | 59.7 (11.4) | 14 | -8.9 (11.4) | -2.945 | (-9.096 to 3.207) | 0.354 |
|  | | | | | | | | | |

\* Expressed as differences (vs. Placebo) in adjusted means (ANCOVA, adjusted for baseline outcome and diabetes stays) with corresponding 95% CIs.